Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EECOH-1: Phase III trial of XW003 injection in adults with type 2 diabetes mellitus
CTR20223156Phase 3Completed
- Sponsor
- Sciwind Biosciences
- Start
- Dec 2022
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of ecnoglutide in type 2 diabetes mellitus (T2DM), sponsored by Sciwind Biosciences. Started Dec 2022; status: completed.
02
Drugs
ecnoglutide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on CTR20223156.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20223156.